-
CYP2C9*3 polymorphism genotype and allele frequency were not statistically different between the case and control Ankylosing Spondylitis groups (P>0.05). the efficacy of NSAID in treatment of AS and COX-2 (显示 COX2 ELISA试剂盒) gene -1290A/G and -1195G/A polymorphism were associated (all P<0.05), but it is not associated with CYP2C9 *3 polymorphism (all P>0.05).
-
polymorphisms c.98T>C in the UGT1A9 (显示 UGT1A9 ELISA试剂盒) and c.1075A>C in the CYP2C9 genes did not affect the pharmacokinetic profile of propofol
-
Possession of CYP2C9*2 and/or CYP2C9*3 allele variants is associated with lower time of international normalized ratio (INR (显示 INSR ELISA试剂盒)) in the therapeutic range (TTR (显示 TTR ELISA试剂盒)) values and warfarin dose variations in aortic valve replacement patients, the latter affected also by VKORC1 (显示 VKORC1 ELISA试剂盒) c.-1693G>A polymorphism
-
Three SNPs (CYP2C9 *2, *3 and VKORC1 (显示 VKORC1 ELISA试剂盒) c.-1639G > A) were genotyped by electrochemical detection using a sandwich-type format that included a 3' short thiol capture probe and a 5' ferrocene-labeled signal probe.
-
This study was aimed to describe the distribution of CYP2C9 and CYP2C19 (显示 CYP2C19 ELISA试剂盒) alleles and haplotypes in four Mestizo populations from Western Mexico. Frequencies ranged from 2.2-3.0% and 4.8-8.9% for CYP2C9*3 and CYP2C9*2 alleles, respectively, and 5.4-12.0% for CYP2C19 (显示 CYP2C19 ELISA试剂盒)*2, whereas the CYP2C19 (显示 CYP2C19 ELISA试剂盒)*3 allele was not found.
-
CYP2C9 IVS8-109 T carriers showed significantly higher dose-corrected phenoytoin blood concentrations and this allele was found in a higher frequency in epileptic patients with supratherapeutic phenytoin levels.
-
Med25 (显示 MED9 ELISA试剂盒), a variable member of the Mediator complex, is a coactivator of ligand-activated ERalpha (显示 ESR1 ELISA试剂盒) that interacts with ERalpha (显示 ESR1 ELISA试剂盒) through its C-terminal LXXLL motif after BPA (显示 DST ELISA试剂盒) exposure, and is functionally involved in BPA (显示 DST ELISA试剂盒)-induced transcriptional regulation of CYP2C9 expression and enzyme activity.
-
We conclude that CYP2C9/2C19 genotype is not relevant for variability in valproic acid exposure.
-
Our results show that anticoagulated patients have a high risk of adverse events if they are carriers of 1 or more genetic polymorphisms in the VKORC1 (显示 VKORC1 ELISA试剂盒) (rs9923231) and CYP2C9 (rs1799853 and rs1057910) genes.
-
Review/Meta-analysis: CYP2C9 gene polymorphism was significantly associated with decreased warfarin maintenance dose requirements in pediatric patients.
